A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma

被引:23
作者
Alasker, Ahmed [1 ,4 ]
Meskawi, Malek [1 ]
Sun, Maxine [1 ]
Ismail, Salima [1 ,4 ]
Hanna, Nawar [1 ,4 ]
Hansen, Jens [1 ,3 ]
Tian, Zhe [1 ]
Bianchi, Marco [1 ,2 ]
Perrotte, Paul [4 ]
Karakiewicz, Pierre I. [1 ,4 ]
机构
[1] Univ Montreal Hlth Ctr, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
[2] Univ Vita Salute San Raffaele, Urol Res Inst, Dept Urol, Milan, Italy
[3] Prostate Canc Ctr Eppendorf Hamburg, Martini Clin, Hamburg, Germany
[4] Univ Montreal, Dept Urol, Montreal, PQ, Canada
关键词
Side effects; Targeted therapy; Renal cell carcinoma; Adverse events; QUALITY-OF-LIFE; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; FOOT SKIN REACTION; NASAL-SEPTUM PERFORATION; RANDOMIZED PHASE-II; INTERFERON-ALPHA; JAPANESE PATIENTS; SUNITINIB TREATMENT; KINASE INHIBITORS; MAMMALIAN TARGET;
D O I
10.1016/j.ctrv.2012.12.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: To provide an updated review of adverse events associated with sunitinib, pazopanib, bevacizumab, temsirolimus, axitinib, everolimus and sorafenib and their management. Materials and methods: We performed a PubMed and Cochrane-based review of side effects associated with the seven agents including product monographs to provide an outline of treatment measures aiming to reduce their toxicities. Subject and outcome of interest, design type, sample size, pertinence and quality, and detail of reporting were the indicators of manuscript quality. Results: All targeted therapies cause adverse events. Most adverse events may be prevented or tested before they escalate to severe levels. Conclusion: Prevention, early recognition, and prompt management of side effects are of key importance and avoid unnecessary dose reductions, which may undermine treatment efficacy. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:388 / 401
页数:14
相关论文
共 133 条
[1]
Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis [J].
An, Mao Mao ;
Zou, Zui ;
Shen, Hui ;
Liu, Ping ;
Chen, Meng Li ;
Cao, Yong Bing ;
Jiang, Yuan Ying .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (08) :813-821
[2]
[Anonymous], AV PACK INS
[3]
[Anonymous], AF PACK INS
[4]
[Anonymous], 2009, DRUG INT
[5]
[Anonymous], ART HYP, V2007
[6]
[Anonymous], 2012, GASTR COMPL
[7]
[Anonymous], SUT PACK INS
[8]
[Anonymous], VOTR PACK INS
[9]
[Anonymous], TOR PACK INS
[10]
[Anonymous], NAT COMPR CANC NETW